NASDAQ · Financial Statements
Eucrates Biomedical Acquisition Corp. (EUCR) Financial Statements
$10.04
NASDAQ: EUCR
Market Cap $42.23M
Overview Financials Dividend Eucrates Biomedical Acquisition Corp. most recently reported annual revenue of $0, net profit of $6.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 Revenue $0 $0 $0 Operating Profit $0 $-1.0M $-1.0M Net Profit $0 $4.0M $6.0M EPS $0.00 $0.28 $1.86 Op Margin — — —
Balance Sheet (USD)
Metric 2020 2021 2022 Total Assets $106.0M $105.0M $12.0M Total Liabilities $4.0M $6.0M $4.0M Cash $1.0M $0 $0 Borrowings $0 $0 $0
Cash Flow (USD)
Metric 2020 2021 2022 Operating Cash Flow — $-1.0M $-1.0M Investing Cash Flow — $0 $93.0M Financing Cash Flow — $0 $-186.0M Net Cash Flow — $-1.0M $0 Free Cash Flow $0 $-1.0M $-1.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.13 EV / EBITDA -60.47 FCF Yield -1.49% Quick Ratio 2.03 Interest Coverage 0.00 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock